Washington (Bloomberg) – Johnson & Johnson’s Covid-19 vaccine has been revised by US regulator, Food and Drug Administration, to warn about the risk of a rare bleeding disorder. It told the company an increased risk of immune thrombocytopenia, or ITP, during the 42 days following vaccination can occur. Symptoms include bruising or excessive or unusual bleeding, according to the agency.
